Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre–post design study
- 297 Downloads
Abstract
Background Albumin is a protein colloidal solution with limited availability and high cost. It should be used in such approved indications as paracentesis, extensive burn, spontaneous bacterial peritonitis, and nephrotic syndrome. Objectives The aim of this study was to evaluate and compare the appropriateness of albumin usage before and after an evidence-based guideline. Setting Four wards of Imam Reza Hospital, Mashhad, Iran. Method An interventional pre–post design study was performed on 2 groups of patients; in gGroup 1 as a preparation phase group in 6 months from February 2015 to July 2015 and Group 2 as an interventional group from September 2015 to February 2016. A guideline for proper indications of albumin, designed and finalized based on the physicians’ comments, was implemented in Group 2. Main outcome measure The pattern of albumin consumption. Results Fifty patients were evaluated in each group. The implementation of the guideline resulted in reduction of improper albumin use from 62 to 57.5%, which was not statistically significant; however., it reduced inappropriate dose and duration of albumin therapy (55.5–16.7%), the number of consumed albumin vial, and the average cost for each patient (317.78 ± 3.15–149.81 ± 1.91 USD) significantly, as well. Conclusion This study illustrated that in this hospital in most cases, albumin was used inappropriately and at an alarming rate. This improved after the introduction of an evidence-based guideline. Moreover, guideline implementation resulted in significant cost reduction.
Keywords
Albumin Cost reduction Drug use evaluation (DUE) Inappropriate use Intervention Iran Teaching hospitalNotes
Acknowledgements
This study is part of a research thesis for a Pharm.D. degree at Mashhad University of Medical Sciences. The authors are thankful for the funding of this study by the Research Council of Mashhad University of Medical Sciences.
Funding
Mashhad University of Medical Sciences.
Conflicts of interest
None.
Supplementary material
References
- 1.Kazemi Y, Hadavand N, Hayatshahi A, Torkamandi H, Gholami K, Hadjibabaie M, et al. Albumin utilization in a teaching hospital in Tehran: time to revise the prescribing strategies. J Pharm Care. 2013;1(4):127–32.Google Scholar
- 2.Bowman I. Drug use evaluation is DUE: healthcare utilization evaluation is over-DUE. Hosp Pharm. 1996;3:5–8.Google Scholar
- 3.Talasaz AH, Jahangard-Rafsanjani Z, Ziaie S, Fahimi F. Evaluation of the pattern of human albumin utilization at a university affiliated hospital. Arch Iran Med. 2012;15(2):85–7.PubMedGoogle Scholar
- 4.Namazi S, Karimzadeh I. Drug utilization evaluation of unfractionated heparin in a cardiac care unit in Iran. J Pharm Res. 2011;4(5):1470–2.Google Scholar
- 5.Mahmoudi L, Karamikhah R, Mahdavinia A, Samiei H, Petramfar P, Niknam R. Implementation of pharmaceutical practice guidelines by a project model based clinical and economic impact. Medicine. 2015;94(42):e1744.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Jahangard-Rafsanjani Z, Javadi MR, Torkamandi H, Alahyari S, Hajhossein Talasaz A, Gholami KH. The Evaluation of albumin utilization in a teaching university hospital in Iran. IJPR. 2011;10(2):385–90.PubMedPubMedCentralGoogle Scholar
- 7.Caraceni P, Domenicali M, Tovoli A, Napoli L, Serena Ricci C, Tufoni M, Bernard M. Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med. 2013;24:721–8.CrossRefPubMedGoogle Scholar
- 8.WHO medicines strategy: framework for actions in essential drugs and medicines policy; 2000–2003. Geneva: World Health Organization. From World Health Organization on the World Wide Web: http://apps.who.int/medicinedocs/pdf/whozip16e/whozip16e.pdf.
- 9.American Hospital Formulary Service® (AHFS™) Drug Information 2009. Bethesda: American Society of Health System Pharmacists. From AHFS on the World Wide Web: http://www.ahfsdruginformation.com/.
- 10.Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G. Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009;7(3):216–34.PubMedPubMedCentralGoogle Scholar
- 11.Aramwit P, Kasettratat N. Evaluation of serum albumin utilization in inpatient at a private hospital in Bangkok. Yakugaku Zasshi. 2004;124(9):631–4.CrossRefPubMedGoogle Scholar
- 12.Vargas E, de Miguel V, Portole A, Avendano C, Ambit M, Torralba A, Moreno A. Use of albumin in two Spanish university hospitals. Eur J Clin Pharmacol. 1997;52:465–70.CrossRefPubMedGoogle Scholar
- 13.Somers A, Bauters T, Robays H, Bogaert M, Colardyn F. Evaluation of human albumin use in a university hospital in Belgium. Pharm World Sci. 2002;24(3):111–6.CrossRefPubMedGoogle Scholar
- 14.Tanzi M, Gardner M, Megellas M, Lucio S, Restino M. Evaluation of the appropriate use of albumin in adult and pediatric patients. Am J Health Sys Pharm. 2003;60:1330–5.Google Scholar
- 15.Marwick C. Pharmacoeconomics: is a drug worth its cost? JAMA. 1994;272:1395.CrossRefPubMedGoogle Scholar
- 16.Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008;36:427–33.CrossRefPubMedGoogle Scholar